67DKK
4.35 BDKK
16.47 BDKK
63.62 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Employees (FY)
2.2 K
Founded
1998
ISIN
DK0010272202
FIGI
BBG000BKPC99
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where GMAB is featured.
Frequently Asked Questions
The current price of GMAB is 2023 DKK — it has decreased by 0.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXCOP exchange GENMAB A/S stocks are traded under the ticker GMAB.
GENMAB A/S is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
GMAB stock is 1.53% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is GENMAB A/S there?
GMAB earnings for the last quarter are 32.32 DKK per share, whereas the estimation was 22.87 DKK resulting in a 41.35% surprise. The estimated earnings for the next quarter are 21.52 DKK per share. See more details about GENMAB A/S earnings.
GENMAB A/S revenue for the last quarter amounts to 4.74 B DKK despite the estimated figure of 4.49 B DKK. In the next quarter revenue is expected to reach 4.61 B DKK.
Yes, you can track GENMAB A/S financials in yearly and quarterly reports right on TradingView.
GMAB stock has fallen by 1.80% compared to the previous week, the month change is a 0.34% fall, over the last year GENMAB A/S has showed a 27.70% decrease.
GMAB net income for the last quarter is 640.00 M DKK, while the quarter before that showed 2.13 B DKK of net income which accounts for −69.94% change. Track more GENMAB A/S financial stats to get the full picture.
Today GENMAB A/S has the market capitalization of 132.72 B, it has increased by 0.10% over the last week.
No, GMAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GMAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENMAB A/S stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 2.20 K employees. See our rating of the largest employees — is GENMAB A/S on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENMAB A/S technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENMAB A/S stock shows the neutral signal. See more of GENMAB A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GENMAB A/S future price: according to them, GMAB price has a max estimate of 3436.33 DKK and a min estimate of 1860.00 DKK. Read a more detailed GENMAB A/S forecast: see what analysts think of GENMAB A/S and suggest that you do with its stocks.